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A B S T R A C T
Purpose: There is a lack of information from South America regarding factors that predict the clinical
outcomes of patients treated medically for mesial temporal lobe epilepsy with hippocampal sclerosis
(MTLE-HS). This study was conducted to determine which of these factors are the most important.
Methods: This study included 110 South American patients with MTLE-HS treated with antiepileptic
drugs. The factors considered included age, gender, age of epilepsy onset, interval between the lesion and
the ﬁrst seizure, central nervous system infection, traumatic brain injury, perinatal asphyxia, febrile
convulsion, history of status epilepticus, types of seizures, site of hippocampal sclerosis (HS),
extrahippocampal pathology, and electroencephalogram (EEG) abnormalities. The patients were divided
into two groups based on the response to treatment: Group I, seizure free for at least two years; and
Group II, not seizure free.
Results: On the multivariate analysis, the factors associated with a poor prognosis in terms of seizure
frequency and control following treatment included the presence of an early onset of seizure, more than
10 seizures per month before treatment, and EEG abnormalities.
Conclusion: The recognition of risk factors, such as early onset of seizures, more than 10 seizures per
month before treatment, and EEG abnormalities, could lead to the identiﬁcation of risk groups among
patients with MTLE-HS and refractory epilepsy, possibly designating these individuals as candidates for
early epilepsy surgery.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Hippocampal sclerosis (HS) is the most common pathology in
the brain of patients with drug-resistant mesial temporal lobe
epilepsy (MTLE).1–4 HS is present in 50–70% of cases in which a
temporal lobectomy was performed for the treatment of refractory
epilepsy.5–7 Various studies have conﬁrmed that MTLE-HS is a
chronic disease characterised by prominent neuronal loss and
ﬁbrillary gliosis at the level of the hippocampal pyramidal cell
layer, but the pathophysiological mechanisms of HS are not
clear.2,8,9
Early surgery is typically recommended because uncontrolled
epilepsy is associated with cognitive impairment, psychosocial
dysfunction, and increased morbidity and mortality. It has been
found that if refractoriness is detected early, aggressive drug
therapy or early surgery can improve the responsiveness to
treatment and minimise these adverse effects.10,11* Corresponding author. Tel.: +593 42 292953.
E-mail address: javiersanchez503@yahoo.com (J. Sa`nchez).
http://dx.doi.org/10.1016/j.seizure.2014.03.003
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reReports of seizure remission in patients with MTLE-HS range
from 5%12 to 42%.3 An early onset of epilepsy, history of febrile
convulsions, interictal epileptiform activity on electroencephalo-
gram (EEG), duration of epilepsy, response to the ﬁrst antiepileptic
drug, number of seizures per month before treatment, presence of
mental retardation, age of traumatic brain injury(TBI), dual
pathology,2 and female gender13–16 are prognostic factors in
MTLE-HS. The majority of research studies on the prognostic
factors of medically treated MTLE-HS have been conducted in
developed countries, but of the approximately 70 million people
with epilepsy in the world, 80% (56 million) live in developing
countries.17 The purpose of this study was to identify the
prognostic factors in patients with medically treated MTLE-HS
in South America.
2. Methods
We conducted a prospective study of 110 patients who met the
inclusion criteria described below and who were treated at the
Department of Neurology, Institute of Neurosciences, in Guayaquil,
Ecuador, between January 2008 and December 2010. This instituteserved.
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country and primarily serves a low-income population. The
patients were diagnosed according to the criteria proposed by
the International League Against Epilepsy (ILAE), which include
seizure semiology, EEG, and magnetic resonance imaging (MRI)
ﬁndings.18We only considered seizure semiology and MRI ﬁndings
as the inclusion criteria. We did not consider EEG as an inclusion
criterion because the standard 30-min EEG in patients with mesial
temporal lobe epilepsy can be normal or indeterminate, which
does not rule out the presence of MTLE-HS; ictal epileptiform
activity is nearly all always detected using long-term EEG
monitoring or repeated standard EEGs.9 We conducted medical
histories with an emphasis on seizure semiology. We conducted
conventional EEGs using 18 digital channels for 30 min, following
the international standards requiring the placement of 10–20
electrodes. The studies were conducted using an Intera1.5 Teslas
MRI instrument (Philips Healthcare, Andover, MA, USA) in
weighted sequences in T1, T2, FLAIR, and IR T1. The protocol
comprised the following: (a) sagittal T1 SPIN-ECHO, with a ﬁeld-of-
view (FOV) of 22 cm, a thickness of 4.5 mm at 1 mm; intervals, TR
597 ms, TE 15 ms, 448 reconstruction matrix, yielding 22 sagittal
slices; (b) axial T1 SPIN-ECO, with a FOV of 23 cm, a thickness of
4.5 mm at 1 mm intervals, TR 450 ms, TE 15 ms, 256 reconstruc-
tion matrix, yielding 22 axial slices parallel to the corpus callosum;
(c) axial T2 TURBO SPIN-ECHO, FOV of 23 cm, a thickness of 4.5 mm
at 1 mm intervals, TR 4882 ms, TE 110 ms, 448 reconstruction
matrix, 908 angle, yielding 22 axial slices parallel to the corpus
callosum; (d) coronal T2 TURBO SPIN-ECHO, FOV of 23 cm,
thickness of 3.5 mm at 1 mm intervals, TR 2000 ms, TE 110 ms,
512 reconstruction matrix, 908 angle, yielding 22 coronal slices
perpendicular to the hippocampal axis; (e) coronal T1-IR, focused
on the hippocampus, with a FOV of 23 cm, thickness of 1.5 mm at
1.2 mm intervals, TR 3064, TE 15 and TI of 400, 576 reconstruction
matrix, yielding 22 coronal slices perpendicular to the hippocam-
pal axis; and (f) coronal FLAIR T2 TURBO SPIN-ECHO, focused on
the hippocampus, with a 23 cm FOV, thickness of 1.5 mm at 1 mm
intervals, TR 600, TE 120 of TI 2000, 576 reconstruction matrix,
1008 angle, yielding 22 coronal slices perpendicular to the
hippocampal axis.
The inclusion criteria for the study were the following: (1)
clinical history and signs of epilepsy corresponding to MTLE,
usually with auras that consisted of epigastric, autonomic, and/or
psychic sensations followed by an arrest of motor activity,
progressive loss of consciousness, and automatisms of the mouth
and hands, with or without secondary generalisation; and (2) MRI
ﬁndings: the presence of atrophy (coronal T1-IR) and/or increased
hippocampal signal (coronal T2 and FLAIR) detected by visual
analysis by 2 neuroradiologists). We analysed the following
factors: age, gender, age at onset of epilepsy, history of febrile
seizures, presence of TBI, infections of the central nervous system
(CNS), perinatal injury, family history of epilepsy, interval
between brain injury and onset of epilepsy, seizure frequency
before the start of treatment with antiepileptic drugs, type of
seizures, site of HS, extrahippocampal pathology, and alterations
in the EEG.
We included patients who were at least ﬁve years old. The onset
of epilepsy refers to the patient’s age when the seizures started,
excluding febrile seizures. The ability to distinguish between
simple febrile seizures (generalised, shorter than 10 min, without
recurrence within 24 h or during the duration of the febrile illness)
and complex febrile seizures (present focal symptomatology,
duration longer than 10 min, occurs two or more times within 24 h
or during the duration of the febrile illness),20 is problematic
because of the amount of time that passes between the onset of a
febrile seizure and the time at which the patient is ﬁrst seen for
their epileptic symptoms. The patients or their relatives aretypically unable to remember the exact duration of the febrile
seizure. Because of this difﬁculty, we did not differentiate between
simple and complex febrile seizures. The identiﬁcation of a patient
as having a suspected CNS infection was primarily based on the
history given by the patient or their relatives and the absence of
other potential aetiological factors for their cases of epilepsy, e.g.,
history of signiﬁcant head trauma, history of febrile convulsions,
history of perinatal injury or non-febrile seizures preceding the
suspected CNS infection.
One potential limitation of our study is that the primary
criterion for the selection of a case of suspected CNS infection or
perinatal asphyxia was the history provided by the patient or their
relatives. It was not possible to obtain deﬁnitive conﬁrmation of
the precise nature of the reported event because it occurred many
years before or was managed at another institution. Many of our
native patients, particularly in rural areas, have home deliveries
without medical assistance. TBI was considered when there was a
loss of consciousness, post-traumatic amnesia, or focal neurologi-
cal signs after a brain injury.21 A family history of epilepsy was
considered in patients who had relatives of at least ﬁrst or second-
degree co-sanguinity with epilepsy. The interval between the brain
injury and the occurrence of the ﬁrst seizure could not be
determined for all the subjects. The interval was established for 94
patients (85.5%). These brain injuries included: febrile seizures,
perinatal asphyxia, CNS infections, and TBI. We considered brain
injuries that occurred before the age of ﬁve. Mathern GW et al.
(1995), in a series of 20 patients, demonstrated that patients who
suffered brain injuries before the age of ﬁve showed signiﬁcant
unilateral hippocampus atrophy versus those who did not.22 The
seizure frequency prior to the initiation of treatment was
considered by calculating the median seizure frequency for the
last three months. The seizure types included simple partial
seizures, complex partial seizures, and secondarily generalised
partial seizures. We included patients with unilateral or bilateral
hippocampal sclerosis and those with additional extra-hippocam-
pal pathology (‘‘dual’’ pathology) according to the ﬁndings of the
MRI. Abnormal electroencephalographic ﬁndings included tempo-
ral intermittent rhythmic delta activity (TIRDA) and/or interictal
epileptiform activity (IEA) of either spike or sharp wave type in the
temporal regions, with maximum electronegativity in the anterior
temple (F7/F8).
Follow-up examinations were performed every two to three
months. After two years of follow-up, the patients were divided on
the basis of the outcomes after medical treatment into two groups.
Group I was seizure free for at least two years, and Group II was not
seizure free.23 We compared the clinical, neurophysiological, and
imaging factors across these two groups of patients using
statistical methods. We made a note of any antiepileptic drugs
used by the patients in both groups.
2.1. Statistical analysis
The statistical analyses were performed with SPSS software
(IBM, Chicago, IL, USA).
The data are presented as the means, standard deviations, and
percentages. The Kolmogorov–Smirnov test was used to determine
the normality of the data distribution, and Levine’s test was used to
assess the homogeneity of variance. Analysis of variance (ANOVA)
or the non-parametric Kruskal–Wallis test were used for continu-
ous variables and normally distributed data. The Chi-squared test
or Fisher’s exact test (when the number of observations was too
small) were used to compare the percentages. P values of <0.05
were considered statistically signiﬁcant. For the multivariate
analysis, we used the Logistic Regression Model with the Enter
Method for variables selection, the Hosmer–Lemeshow test to
determine the goodness of ﬁt of the model (0.629) and the Wald
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3. Results
Data regarding the clinical, neurophysiological, and neuroradio-
logical factors for the 2 groups of patients are presented in Tables 1
and 2. We identiﬁed 45 women (40.9%) and 65 men (59.1%). The
patients’ ages ranged from 8 to 53 years (mean = 31.3  14.5 years).
Thirty-four (31%) patients were in Group I, and 76 (69%) were in Group
II. Of the 110 patients included in the study, 20 (18%) patients were
already receiving monotherapy with subtherapeutic levels of carba-
mazepine (10 patients), oxcarbazepine (ﬁve patients), or valproic acid
(ﬁve patients). Ninety (82%) patients were diagnosed for the ﬁrst time
at the time of the study. After two years of follow-up, of the 34 patients
free of seizures, 20 patients (59%) were on monotherapy and 14
patients (41%) were receiving dual-therapy. Of the 76 patients who
were not seizure free, 70 patients (92%) were receiving dual-therapy,
and six patients (8%) were receiving triple-therapy (Table 3). Carba-
mazepine was the most frequently used antiepileptic drug forTable 1
Univariate logistic regression model and correlation between the clinical, electrophysiol
hippocampal sclerosis.monotherapy. For dual-therapy, the combination of carbamazepine
and levetiracetam was the most common. For triple-therapy, the most
common combination was carbamazepine, valproic acid, and levetir-
acetam. We found 28 patients with right HS (25.5%), 62 patients with
left HS (56.4%), and 20 patients with bilateral HS (18.1%). There were
nine patients with extra hippocampal pathology (dual pathology): ﬁve
patients with brain calciﬁcations (one with left parietal with left HS,
one with left occipital with left HS, two with left temporal calciﬁcations,
one with left HS and one with right HS, and one patient with multiple
brain calciﬁcations with bilateral HS) and four patients with
malformations of cortical development (two patients with focal frontal
dysplasia and hippocampal sclerosis on the same side, one patient with
focal temporal dysplasia on the same side of hippocampal sclerosis, and
one patient with subcortical nodular heterotopia on the same side as
the hippocampal sclerosis). We found three patients with arachnoid
cysts on the same side of the hippocampal sclerosis. Four patients in
Group II had a history of a suspected CNS infection. The presence of
secondarily generalised partial seizures or more than 10 seizures per
month before treatment were associated with poor outcomes with
regard to seizure frequency and seizure control.ogical, and neuroradiological factors in patients with mesial temporal epilepsy with
Table 2
The effect of speciﬁc parameters on prognosis.
Group  I  Group  II  Group  I -II  
Mean 
SD
Mean 
SD p 
n=34 n=7 6 
AGE  (years ) 33 .47  13.5 31 .75 14 .63  0.596*
AGE AT 1st SEIZURE (years) 15.21 10 .09 10 .65 7. 82  0.016*
INTERVAL BETWEEN THE LESION AND FIRST  SEIZURE  (years )  11,24 7. 93 8. 21 7. 98  0.029*
AGE AT TBI (years) 2. 57 1. 13 2. 73 1. 58  0.383
AGE AT  FEBRILE CONV ULSION (years) 2. 59  1.6 2. 35 1. 66  0.687*
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epileptiform activity with spikes (slow waves of 1 Hz) with
maximum anterior temporal electronegativity in the unilateral
temporal region, and 16 (47%) had normal EEG ﬁndings. Of the 76
patients who continued to have seizures, three (4%) had normal EEG
ﬁndings. Of the remaining 73 patients, 52 (68%) had interictal
epileptiform activity, sharp wave and/or spike-slow wave of 1 Hz
with maximum anterior unilateral temporal electronegativity, eight
patients (10.5%) presented unilateral (TIRDA), 11 patients (14.5%)
had TIRDA and unilateral IEA, and two patients (3%) had asynchro-
nous and independent bilateral interictal temporal activity.
When comparing Groups I and II, it became evident that an
earlier age at the ﬁrst seizure was associated with a poorer
outcome than when the ﬁrst seizure occurred later in life. A shorter
interval between the lesion and the ﬁrst seizure was associated
with poor outcomes.
The multivariate analysis indicated that an earlier age at the
ﬁrst seizure, more than 10 seizures per month before treatment,
and EEG abnormalities were independent predictors of a poor
outcome (Table 4).Table 3
AEDs used for medical treatment.
Seizure free for 2
years
n = 34
Not seizure free
n = 76
CBZ 14 25% 0 0%
OXC 5 16% 0 0%
VPA 1 3% 0 0%
CBZ + LVT 7 28% 30 39%
OXC + LVT 4 13% 28 36%
CBZ + VPA 1 3% 12 15%
OXC + VPA 1 6% 0 0%
LTG + VPA 1 6% 1 1%
CBZ + LVT + LTG 0 0% 1 1%
CBZ + LVT + VPA 0 0% 4 8%
AEDs, antiepileptic drugs; LVT, levetiracetam; CBZ, carbamazepine; OXC, oxcarba-
zepine; VPA, valproate; LTG, lamotrigine.Other factors, including age, gender, family history of epilepsy,
perinatal asphyxia, febrile seizures, history of status epilepticus,
central nervous system infections, and extrahippocampal pathol-
ogy, were not associated with the post-treatment outcomes with
regard to seizure frequency and seizure control.
4. Discussion
We presented here a population of 110 cases of MTLE-HS who
were selected based on semiologic and imaging (MRI of the brain)
criteria. We did not include EEG ﬁndings in the criteria because the
standard 30-min EEG in patients with mesial temporal lobe
epilepsy can be normal or indeterminate, although this does not
rule out the presence of MTLE-HE. Interictal epileptiform activity is
frequently detected using long-term EEG monitoring or repeated
standard EEGs.19 Thirty-four patients (31%) remained seizure-free
for at least two years while undergoing therapy with antiepileptic
drugs, showing a range from 5% (Semah F et al. 2000) to 42%
(Stephen L et al., 2001).3 This relative high percentage of patients is
likely due to our hospital being a referral centre for patients with
epilepsy across the country and not solely for patients with
difﬁcult-to-control epilepsy. The majority of patients (76 or 69%)
were not seizure free during the two years of treatment, in
agreement with other published studies (Kim WJ et al., 1999;
Pittau F et al., 2009).1,15 One limit of our study is the decision not to
include EEG, as an inclusion criterion, which may limit the
diagnosis of mesial temporal lobe epilepsy, with mild forms of
hippocampal sclerosis; normally indicated histophatologically;
this EEGs could indicate interictal epileptiform activity, even
though the MRI would suggest otherwise (Holmes MD et al.
2000)34. In our study, we found nine patients (11%) with dual
pathology, ﬁve of which showed cerebral calciﬁcations accompa-
nying HS. This suggests that brain CT (computed tomography)
scans should be performed along with the brain MRI scan and EEG
evaluations in countries where cysticercosis is endemic, as it is in
Ecuador. Three of the patients in Group II were found to have
Table 4
Multivariate logistic regression analysis for predictors of refractory epilepsy.
Wald test
B E.T. Wald gl Sig. Exp (B) 95% CI for EXP(B)
Lower Upper
EEG abnormalities 1.707 .452 14.294 1 .000 5.514 2.276 13.360
More than 10 seizures per month before treatment 1.363 .618 4.872 1 .027 3.909 1.165 13.119
Early onset of seizures .061 .023 7.068 1 .008 .940 .899 .984
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cysts are considered incidental ﬁndings in patients with epilepsy
and do not necessarily reﬂect the location of the epileptic centre.24
The present study found that the presence of more than 10
seizures per month before treatment was a poor prognostic factor.
This ﬁnding is consistent with other published ﬁndings, which
have shown a worsened prognosis with an increased frequency of
pre-treatment seizures.25–29 Patients who had more than 10
seizures per month before treatment were more than twice as
likely to develop refractory epilepsy than the patients who had
fewer seizures.27 The results or our work are not consistent with
the results from a recent study (Gasparini S et al. 2013),30 which
found that the frequency of seizures before the start of treatment
was not a prognostic factor. This could be explained by differences
in the patient populations studied because Gasparini et al. include
patients with cryptogenic focal epilepsy and used hippocampal
sclerosis as an exclusion criterion.
The presence of abnormal EEG ﬁndings (temporal intermittent
rhythmic delta activity and/or interictalepileptiform activity of
spike or sharp wave type in the temporal regions with maximal
anterior temporal electronegativity) was a negative predictor of
seizure control with medical treatment. This result is consistent
with previous studies.1,15,31. Methodological limitations, differ-
ences in how the EEGs are recorded, adoption of different criteria
for ‘‘abnormality’’, and differences in EEG interpretation could alter
the strength of abnormal activity as a predictor of outcomes.15
We found that an earlier the onset of seizures has a worse
prognosis. Although the early onset of seizures has been associated
with a good prognosis,32 the majority of evidence favours the
conclusion that an early onset of seizures correlates with a poor
prognosis.1,15,16,33. On the univariate analysis, predictors of poor
outcomes included an early onset of seizures, more than 10
seizures per month before treatment, EEG abnormalities, a shorter
interval between the lesion and the ﬁrst seizure, secondarily
generalised partial seizures. The multivariate analysis showed an
early onset of seizures, more than 10 seizures per month before
treatment, and EEG abnormalities to be signiﬁcant prognostic
predictors of poor outcomes.
We suggest that the early recognition of poor prognostic factors
would allow for the identiﬁcation of risk groups within the
population of patients with MTLE-HS for development of a
refractory condition to shorten treatment and introduce the
possibility of epilepsy surgery.11,35–37 We believe that this early
detection would help prevent neuropsychological and social
degeneration in these patients.
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